RT Journal Article
SR Electronic
T1 ELF3 Overexpression as Prognostic Biomarker for Recurrence of Stage II Colorectal Cancer
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 191
OP 201
DO 10.21873/invivo.12248
VO 35
IS 1
A1 AYUMI TAKAOKA
A1 TOSHIAKI ISHIKAWA
A1 SATOSHI OKAZAKI
A1 SHUICHI WATANABE
A1 FUYUKI MIYA
A1 TATSUHIKO TSUNODA
A1 AKIFUMI KIKUCHI
A1 SHINICHI YAMAUCHI
A1 TAKATOSHI MATSUYAMA
A1 MASANORI TOKUNAGA
A1 HIROYUKI UETAKE
A1 YUSUKE KINUGASA
YR 2021
UL http://iv.iiarjournals.org/content/35/1/191.abstract
AB Background/Aim: Adjuvant chemotherapy for high-risk Stage II colorectal cancer (CRC) is weakly recommended; however, no consensus exists on “high-risk” definition. Prognostic biomarker identification is important for selecting patients with poor prognosis who may benefit from adjuvant chemotherapy. Materials and Methods: Using Microarray data analyses, ELF3 was identified as a candidate gene highly expressed in Stage II CRC with distant recurrences. ELF3 mRNA expression in 168 Stage II CRC patients was subjected to quantitative RT-PCR analysis and ELF3 protein expression in 185 patients was quantified by immunohistochemical analysis. The relationship between mRNA and protein expression levels and patient characteristics were also investigated. Results: The overall recurrence rate and relapse-free survival were significantly poorer in the ELF3 high-expression than the low-expression group at the mRNA and protein levels. High ELF3 mRNA and protein expression levels were independent poor prognostic factors. Conclusion: High ELF3 expression was associated with recurrence of Stage II.